Top Suppliers:I want be here
Related CAS#:
951382-34-6 4333-21-5
15761-39-4 471-87-4
690655-41-5 38074-72-5
1356931-03-7 83610-54-2
62571-86-2 51782-88-8
1158522-08-7 940364-43-2
134104-43-1 131615-57-1
6906-52-1 1499836-32-6
930439-75-1 1018584-77-4
111370-30-0 1375289-11-4

951382-34-6

951382-34-6 structure
951382-34-6 structure
  • Name: Ipragliflozin L-Proline
  • Chemical Name: (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,(2S)-pyrrolidine-2-carboxylic acid
  • CAS Number: 951382-34-6
  • Molecular Formula: C26H30FNO7S
  • Molecular Weight: 519.58200
  • Catalog: Signaling Pathways Membrane Transporter/Ion Channel SGLT
  • Create Date: 2016-05-20 04:03:58
  • Modify Date: 2024-01-02 10:51:14
  • Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
Name (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,(2S)-pyrrolidine-2-carboxylic acid
Synonyms ASP-1941
Ipragliflozin L-proline
UNII-M6N3GK48A4
Ipragliflozin (L-Proline)
Description Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
Related Catalog
Target

IC50 value: 2.8 nM (SGLT2)[1][2].

In Vitro Ipragliflozin (L-Proline) potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases[3].
In Vivo Ipragliflozin (L-Proline) shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice [3]. Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h[4]. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance [5].
References

[1]. Imamura M, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 15;20(10):3263-79.

[2]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.

[3]. Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36.

[4]. Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36-44.

[5]. Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55.
Molecular Formula C26H30FNO7S
Molecular Weight 519.58200
Exact Mass 519.17300
PSA 167.72000
LogP 2.29790
Storage condition 2-8℃

Chemsrc provides CAS#:951382-34-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 951382-34-6 | Chemsrc address: https://m.chemsrc.com/en/baike/493566.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved